Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2020
December 2020, Vol 11, No 6
December 2020, Vol 11, No 6
Keytruda Approved for Relapsed or Refractory Classical Hodgkin Lymphoma
FDA Approvals, News & Updates
December 2020, Vol 11, No 6
On
October 14, 2020
, the FDA expanded the approval of pembrolizumab (Keytruda; Merck), a PD-1 inhibitor, for the treatment of relapsed or refractory classical Hodgkin lymphoma in adults and for refractory classical Hodgkin lymphoma or classical Hodgkin lymphoma in pediatric patients that has relapsed after receiving ≥2 lines of therapy. The FDA granted pembrolizumab orphan drug and breakthrough therapy designations for this indication.
Read Article
Keytruda plus Chemotherapy Approved for Unresectable or Metastatic Triple‑Negative Breast Cancer
Breast Cancer
,
FDA Approvals, News & Updates
December 2020, Vol 11, No 6
On
November 13, 2020
, the FDA accelerated the approval of pembrolizumab (Keytruda; Merck), a PD-1 inhibitor, plus chemotherapy, for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) in patients with PD-L1 (combined positive score [CPS] ≥10), as determined by an FDA-approved test.
Read Article
Gavreto, a New RET Inhibitor, Now Approved for Thyroid Cancer with RET Fusions
FDA Approvals, News & Updates
,
Thyroid Cancer
December 2020, Vol 11, No 6
On
December 1, 2020
, the FDA accelerated the approval of a new indication for pralsetinib (Gavreto; Blueprint Medicines), a
RET
kinase inhibitor, for the treatment of patients aged ≥12 years with advanced or metastatic medullary thyroid cancer and
RET
mutation who require systemic therapy or for patients with thyroid cancer and
RET
fusion who require systemic therapy and whose tumor is refractory to radioactive iodine, if radioactive iodine is appropriate.
Read Article
Oral Onureg First Drug Approved for Adults with AML in Remission
FDA Approvals, News & Updates
,
Leukemia
December 2020, Vol 11, No 6
On
September 1, 2020
, the FDA approved azacitidine (Onureg; Celgene), an oral nucleoside metabolic inhibitor, for maintenance treatment of adults with acute myeloid leukemia (AML) who had first complete remission (CR) or CR with incomplete blood count recovery after intensive induction chemotherapy and who are not candidates for intensive curative therapy. The FDA granted azacitidine an orphan drug designation and used its priority review for this indication.
Read Article
Danyelza Receives FDA Approval for High-Risk Neuroblastoma in the Bone and Bone Marrow
FDA Approvals, News & Updates
December 2020, Vol 11, No 6
On
November 25, 2020
, the FDA granted accelerated approval to naxitamab-gqgk (Danyelza; Y-mAbs Therapeutics), a GD2-binding monoclonal antibody, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of relapsed or refractory high-risk neuroblastoma in the bone or bone marrow in pediatric patients aged ≥1 year and adults who achieved a partial response, minor response, or stable disease after receiving previous therapy. The FDA granted naxitamab priority review and breakthrough therapy, orphan drug, and rare pediatric disease designations.
Read Article
FDA Approves First Prostate-Specific Membrane Antigen–Targeted PET Imaging Drug for Prostate Cancer
FDA Approvals, News & Updates
,
Prostate Cancer
December 2020, Vol 11, No 6
On
December 1, 2020
, the FDA approved Gallium 68 PSMA-11 (Ga 68 PSMA-11; University of California), the first drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer. Ga 68 PSMA-11 is indicated for men with suspected metastatic prostate cancer that may be curable by surgery or by radiation, and for suspected recurrent prostate cancer based on elevated serum prostate-specific antigen (PSA) levels.
Read Article
Xevinapant Improves Overall Survival in Patients with Head and Neck Squamous-Cell Carcinoma
By
Phoebe Starr
Emerging Therapies
December 2020, Vol 11, No 6
Xevinapant, an investigational antagonist of IAPs (inhibitor of apoptosis proteins), prolonged overall survival (OS) in patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) when added to chemoradiotherapy, according to an updated analysis of a phase 2 clinical trial that was presented at the 2020 European Society for Medical Oncology (ESMO) congress.
Read Article
Dual RAF/MEK Inhibitor Shows Promising Activity in Tumors with RAS/RAF Mutations
By
Wayne Kuznar
Emerging Therapies
December 2020, Vol 11, No 6
VS-6766, a unique inhibitor of the
RAF/MEK
-signaling pathway, has shown antitumor activity in
RAS/RAF
mutation–positive solid tumors and in multiple myeloma, when administered on an intermittent dosing schedule, according to recently published data.
Read Article
Sotorasib, First-in-Class KRAS G12C Inhibitor, Hailed as “Triumph of Drug Discovery”
By
Phoebe Starr
Emerging Therapies
December 2020, Vol 11, No 6
Sotorasib, an investigational small-molecule inhibitor of the
KRAS
p.G12C mutation, demonstrated promising activity and encouraging safety in patients with advanced solid tumors, in particular those with non–small-cell lung cancer (NSCLC), in the preliminary phase 1 CodeBreaK 100 trial. The findings were presented at the 2020 virtual meeting of the European Society for Medical Oncology (ESMO) and were recently published.
Read Article
Social Determinants of Health in Cancer Care
By
Chase Doyle
ASCO Quality Care Symposium
,
Social Determinants
December 2020, Vol 11, No 6
Cancer does not discriminate based on social status, race, income, or education, but that does not mean that it is an equal-opportunity killer. Evidence shows that overall, patients with poorer socioeconomic status also have poorer health outcomes compared with those with good socioeconomic status. The American Society of Clinical Oncology (ASCO) has recently launched a program to address the role of social determinants of health in cancer care and cancer outcomes.
Read Article
Page 3 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma